Pfizer says it raked in $36,800,000,000 in COVID-19 vaccine sales

Pfizer made nearly $40 billion from the COVID-19 vaccine in 2021, making it among the best-selling drugs in history, and expects to bring in $50 billion from the vaccine and the Paxlovid therapeutic in 2022.
Pfizer reports annual profits of $22 billion, more than double the 2020 level. Annual revenues nearly doubled to $81.3 billion, with $36.8 billion from the COVID-19 vaccine.